Adil Debbagh, Khaoula Alaoui Slimani, Yassir Sbitti, Hassan Errihani and Mohammed Ichou
Background: Bladder cancer is the most common malignancy of urinary tract with high rate of morbidity and mortality. Platinum-based chemotherapy remains the first line treatment of advanced disease. Despite several studies, the place of targeted therapies is not yet defined, whereas immunotherapy is currently the standard of care in second-line treatment.
Materials and methods: A comprehensive search of MEDLINE/Pubmed and Embase was conducted to identify conference abstracts, basic science, original and review articles in English.
Conclusion: This review of the literature will discuss the molecular mechanisms involved in tumor progression, the current management of metastatic bladder cancer and future potential treatment modalities.